Abstract Thrombin's role in the nervous system is not well understood. Under conditions of blood-brain barrier compromise (e.g., neurosurgery or stroke), thrombin can result in neuroapoptosis and the formation of glial scars. Despite this, preconditioning with thrombin has been found to be neuroprotective in models of cerebral ischemia and intracerebral hemorrhage. We investigated the effects of physiologically relevant concentrations of thrombin on cortical neurons using two culture-based assays. We examined thrombin's effect on neurites by quantitative analysis of fluorescently labeled neurons. To characterize thrombin's effects on neuron survival, we spectrophotometrically measured changes in enzymatic activity. Using receptor agonists and thrombin inhibitors, we separately examined the role of thrombin and its receptor in neuroprotection. We found that low concentrations of thrombin (1 nM) enhances neurite growth and branching, neuron viability, and protects against excitotoxic damage. In contrast, higher concentrations of thrombin (100 nM) are potentially detrimental to neuronal health as evidenced by inhibition of neurite growth. Lower concentrations of thrombin resulted in equivalent neuroprotection as the antifibrinolytic, aprotinin, and the direct thrombin inhibitor, argatroban. Interestingly, exogenous application of the species-specific thrombin inhibitor, antithrombin III, was detrimental to neuronal health; suggesting that some endogenous thrombin is necessary for optimal neuron health in our culture system. Activation of the thrombin receptor, protease-activated receptor-1 (PAR-1), via micromolar concentrations of the thrombin receptor agonist peptide, TRAP, did not adversely affect neuronal viability. An optimal concentration of thrombin exists to enhance neuronal health. Neurotoxic effects of thrombin do not involve activation of PAR receptors and thus separate pharmacologic manipulation of thrombin's receptor in the setting of direct thrombin inhibitors could be a potential neuroprotective strategy.
Introduction
In addition to its central role in clot formation, thrombin is a promiscuous enzyme with multiple effects in systems besides coagulation; these include the immune system [1] and the nervous system [2] . Thrombin's role as a key modulator of cell growth, development, and response to injury in the nervous system appears to be dynamically modulated by concentration [3] . Thrombin concentrations as low as 1-10 nM can influence glial cell mitosis and motoneuron outgrowth during the embryonic period, while higher concentrations ([100 nM) have been shown to induce apoptosis [4] . Although much of the work on thrombin's central nervous system (CNS) effects have concentrated on trauma or stroke, there is evidence that brain-derived thrombin plays an important role in CNS function. For example, low concentrations (\1 nM) have been associated with augmenting long-term potentiation, a synaptic correlate of memory [5] . Furthermore, thrombin and its propeptide, prothrombin, are produced by neurons and glia in the CNS [6, 7] . Clinical studies have postulated that thrombin regulation may play an important role in the neurodegeneration associated with Alzheimer's Disease [8] and Multiple Sclerosis [9] .
Thrombin's cellular effects are mediated through the activation of protease activated receptors (PARs). To date, four PAR receptors (PAR1-4) have been identified. PAR1, PAR3, and PAR4 can all be activated by thrombin while PAR2 is activated by trypsin and mast cell tryptase (reviewed in [10] ). Thrombin activates the receptor via proteolysis, causing release of a small peptide and an unmasking of a new N-terminal domain. After cleavage the new domain acts as a tethered ligand that binds to the receptor to initiate its G-protein coupled subunit signaling [11] . Similar to its endogenous activator, thrombin, PAR-1 has been associated with both neurotoxicity [12] and neuroprotection [5] .
Self-activation of the PAR receptors results in many downstream second messenger pathways such as stimulation of phosphoinositidase C activity, calcium mobilization, activation of protein kinase C, stimulation of Ras and Ras related proteins, stimulation of tyrosine kinases, inhibition of adenylyl cyclase, and activation of mitogen activated kinase (MAP kinase) and phosphoinositide 3-kinase (PI3 kinase) [11] . Thrombin-mediated stimulation of the receptor is inactivated via phosphorylation of serine or threonine residues in the cytoplasmic tail which targets the receptor internalization and lysosomal digestion [13] . The amino acids of this new N-terminal domain are SFLLRN (Ser-Phe-Leu-Leu-Arg-Asn). Several PARs can be activated by exogenous administration of the peptide sequence that resembles the tethered ligand. This short peptide is called thrombin receptor activation peptide (TRAP). Proteomic data suggests that TRAPs such as SFLLRN can mimic many of the cellular actions of thrombin through receptor activation and activate the same intracellular cascades [14] . The role of TRAP in neuronal health remains largely unexplored.
In this paper, we investigated the effects of thrombin on cortical neuron survival and morphology using rat primary cortical neuron-enriched cultures Through the use of TRAP and thrombin inhibitors we examined the role of thrombin and its receptor in neuroprotection. Additionally, control of thrombin concentration via direct thrombin inhibitors may preserve neuronal health in conditions of high thrombin (neurotrauma or neurosurgery) and represent a novel avenue for pharmacologic therapies.
Materials and Methods

Materials
All cell culture reagents were from Sigma-Aldrich Inc. (St. Louis, MO, USA) unless otherwise specified. Enzymatic proteins were reconstituted in stock solutions as balanced salt solutions and freshly dissolved in media before application. Specific concentrations (see text) of bovine thrombin, argatroban, aprotinin, glutamate, rat antithrombin III, and thrombin receptor activating peptide (TRAP) were applied directly to the media in wells containing cortical neuron cultures (see below). Unless otherwise stated, all test substances and culture reagents were obtained from Sigma (Sigma, Inc., St. Louis, MO).
The physiologic concentrations of free thrombin during coagulation reactions is estimated to vary from 1 nM (0.1 U/mL) to over 500 nM [15] . As several different units of measure exist for thrombin and other proteins related to blood coagulation, we represent concentrations of thrombin, argatroban and TRAP in molarity. For this study, we represent antithrombin III as a percentage of human serum levels. Our calculations are based on published plasma levels; 100 % serum activity is equivalent to 20 mg/dL [16] . Although the exact brain parenchymal levels of thrombin and other coagulation proteins are not known, we based our chosen concentrations on published results of circulating (serum) levels for thrombin [17] and antithrombin [18] . Test concentrations for aprotinin were based on previous work focusing on neuroprotection [19] . Argatroban levels are based on previous work focusing on in vitro thrombin binding assays [20] .
Rat Dissociated Neuron Cultures
All animal procedures were carried out according to the Atlanta VA Medical Center IACUC and adhered to the NIH guidelines for the care and use of laboratory animals. Cortical neurons were dissected from E18 SpragueDawley rat embryos (Charles River Laboratory). For dendrite morphometrics, low-density neuronal cultures were prepared by plating dissociated primary neurons in 100 mm dishes (5 9 10 5 cells/100 mm dish) that contained poly-L-lysine (PLL) coated 15 mm diameter glass coverslips as described in [21] and incubated at 37°C with 5 % CO 2 in plating medium (MEM supplemented with 10 % FBS, glucose 0.6 %wt/vol, HEPES). Twohours after plating, the low-density neuronal cultures on the glass coverslips were flipped over into 12 well dishes containing an astroglial monolayer in neurobasal medium (neurobasal medium supplemented with 2 % B27 supplement and 1 % GlutaMax) (all Invitrogen/Life Technologies; Grand Island, NY, USA). Cytosine-Darabinoside (Ara-C) (1 lM) (Fluka/Sigma) was added at day 3 after plating to prevent glial cell proliferation. Media was exchanged every 7 days. For each drug tested, after 7 days DIV, the cell media was removed from the neurons and mixed with the experimental substance dissolved in fresh media. Coverslips (containing neurons) were removed from the astroglia support layer and placed in media with the experimental substance. After 24 h, the neurons were rinsed with fresh media and stained for immunofluorescence. For MTT assay experiments, cortical neurons were plated at 30,000 cells/well in plating media in 96 well plates previously coated with. After 2 h, plating media was exchanged for neurobasal medium, and glial proliferation was inhibited by the addition of cytosine b-D-arabinofuranoside to 1 lM for 24 h during the second day in vitro. Experimental substances were added to wells 7 days post-plating.
MTT Assay
The yellow tetrazolium salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or MTT, is enzymatically reduced by living cells into an insoluble purple formazan by mitochondria. A spectrophotometer is used to measure the absorption of the resulting colored solution (read absorbance at 595 nm). Twenty-four hours after drug treatment, cell viability was determined as a percentage of control (vehicle-treated cells). A treatment can be considered detrimental to neuronal health if its administration results in fewer viable cells than control [22] . Each experiment had a separate untreated control to which the drug applied groups were compared (represented as 100 %, SD for controls varied between 7.4 and 12.8 %). Much like previous work [19] , we define an exposure to substances that results in more cellular death (and less mitochondrial respiration) as neurotoxic while neuroprotective substances prevent the anticipated amount of death (i.e., compared to untreated controls). We define an exposure to substances that result in more cellular death (and less mitochondrial respiration) as neurotoxic while neuroprotective substances prevent the anticipated amount of death. We do not use the term neuroprotection to describe the ''rescue'' of anticipated neuronal death due to co-application of a known toxic substance (i.e., glutamate; see Fig. 3 ), unless the viability of cells was enhanced beyond untreated cells.
Image Acquisition and Processing
After drug exposure, the cells were rinsed with fresh media and then washed in PBS before adding fixative (1 % PBS, 4 % PFA, 0.1 M Sucrose, dH 2 O) for 20 min. Coverslips were then rinsed in PBS and TBS 50 before permeabilizing the cells in 0.3 % Triton X-100/TBS 50 for 5 min. Cells were then rinsed in 0.1 % Triton X-100/TBS 50 before blocking in blocking buffer (2 % BSA, 2 % FBS (Sigma), 0.1 % Triton X-100, in TBS 50 ) for 1-2 h. Coverslips were then rinsed in buffer (2 % BSA, 0.1 % Triton X-100 in TBS 50 ) and then incubated in primary anti-MAP2 antibody (EMD Millipore; Billerica, MA, USA) at 1:300 at room temperature for 1 h. Secondary fluorescein goat anti-rabbit IgG (Vector Laboratories, Inc.; Burlingame, CA, USA) was then added at 1:500 in the dark after rinsing for 30 min. Coverslips were rinsed and placed on slides with Vectashield fluorescence protection (Vector Laboratories, Inc.; Burlingame, CA, USA). Neurons on slides were viewed and photographed using fluorescent-enabled microscopes (Olympus IX71, Olympus FV1000, Japan) by viewers blinded to experimental conditions. Similarly blinded experimenters were responsible for analyzing and scoring neuronal extensions using the software package ImagePro Express 6.0 (BioVision Technologies; Exton, PA, USA).
Statistical Analysis
Values are expressed as percentage or mean ± SD. Statistical tests were performed with GraphPad InStat (GraphPad Software; La Jolla, CA, USA) and included the t test and one-way ANOVA combined with post-ANOVA Tukey's HSD tests for comparisons between groups. p values of\0.05 are indicated by one asterisk (*), p values of \0.01 are indicated by two asterisks (**), and three asterisks (***) for \0.001.
Results
An Optimal Concentration of Thrombin Enhances the Health of Cortical Neurons in Culture
Neurite extension was influenced by thrombin concentration ( Fig. 1 ). Immunofluorescent staining of antibodies directed at microtubule-associated protein 2 (MAP2) demonstrate the effect of thrombin on neurons in culture. MAP2 is an important cytoskeletal protein that stabilizes dendritic shape and length by cross-linking microtubules to intermediate filaments. Total neurite lengths per neuron (in microns) for the tested thrombin concentrations were (mean ± SD): control, 1315 ± 748; 1 nM, 2941 ± 646; In order to determine if thrombin's inverted U concentration effects on neurites was reflective of thrombin's effect on neuronal viability, the MTT assay was used. Similar to our morphometric assays (Fig. 1 , Panels E and F), Fig. 2 also demonstrates an inverted U effect of thrombin on neuronal health. After 24 h exposure to low concentration (1 nM) thrombin, neuronal survival increased by approximately 10 % (110.2 ± 4.4 %; p value = 0.0004) as compared to control (100 %), presumably through prevention of attrition of neurons in vitro. Moderate concentrations of thrombin (5 and 10 nM) did not significantly alter cell viability (99.5 ± 11.7, and 96.0 ± 21.2 %, respectively) and 24-h exposure to high concentration of thrombin (100 nM) reduced viability by nearly 40 % (60.
Argatroban and Aprotinin Have Neuroprotective Effects Comparable to Nanomolar Concentrations of Thrombin
Molecules involved in coagulation dynamics have been actively investigated for neuroprotection [23, 24] . The effects of argatroban (a direct thrombin inhibitor) and the antifibinolytic, aprotinin, on neuronal survivability were examined and compared to thrombin using the MTT assay. Aprotinin inhibits plasmin and was previously used in cardiac surgery to decrease the need for blood transfusions until concerns over its renal effects resulted in restrictions in its use. No neurotoxicity was observed at any tested aprotinin concentration, and 100 kIU/mL aprotinin enhanced neuronal viability [50 kIU/mL, 99.4 ± 34.4 %; 100 kIU/mL, 133 ± 5.7 % (p \ 0.001); and 200 kIU/mL, 110.4 ± 31.6 %]. Argatroban is used to prevent clot formation in heparin allergic patients or those at risk for heparin-induced thrombocytopenia. At all concentrations of argatroban a mild neuroprotective effect was noted [0.04 lM, 106 ± 6.6 % (p \ 0.05); 0.4 lM, 116 ± 2.6 % (p \ 0.0001); 4 lM, 111.7 ± 10.0 % (p \ 0.05)]. In summary, both afforded neuroprotection comparable to low concentrations of thrombin when exogenously applied in the micromolar and kIU/mL concentration range, respectively (Fig. 3a) .
When neurotoxicity was enhanced with the co-application of glutamate, nanomolar concentrations of thrombin (Fig. 3b) produced a more pronounced neuroprotective effect than aprotinin (Fig. 3c) . In the presence of 24-h exposure to 250 lM glutamate, low-concentration thrombin not only reversed the excitotoxic effects of glutamate but also maintained its ability to enhance neuronal viability [1 nM, 124.9 ± 1.9 % (p \ 0.0001); 5 nM, 100.9 ± 18.2 %; 10 nM, 103 ± 37.8 %; 100 nM, 100.4 ± 35.2 %]. Interestingly, in the setting of 24-h exposure to both 250 lM glutamate and 100 nM thrombin, no adverse effects on neuronal health were noted. It was expected that the co-application of glutamate and the neurotoxic level (100 nM) of thrombin (see Fig. 2 ) would have produced profound neuronal destruction in this assay. This result highlights the complex relationship of thrombin and neuronal health (see ''Discussion'').
In the presence of the same excitotoxic insult (Fig. 3c) , aprotinin protected neurons against glutamate-induced neurotoxicity but did not enhance neuron viability above control conditions. In concordance with the experiments described in Fig. 2 , 24-h exposure to glutamate resulted in a similar reduction in neuron viability relative to control [81.3 ± 16.2 %, p \ 0.05)]. At all tested concentrations, aprotinin appeared to rescue viability from damage due to glutamate, but in contrast to low-concentration thrombin (1 nM), did not result in an increase in cell viability [50 kIU/mL, 110.6 ± 46.7 %; 100 kIU/mL, 115.6 ± 39.8 %; 200 kIU/mL, 107.3 ± 31.9 %].
Serum Levels of Antithrombin III Result in Decreased Neuron Viability
In order to determine if an endogenous thrombin inhibitor also exhibits neuroprotection, exogenous application of antithrombin III (AT III), the most abundant endogenous thrombin inhibitor, was investigated via MTT assays. AT Fig. 2 The effect of exogenously applied thrombin on viability of cultured cortical neurons. Viability was measured using the MTT assay (see ''Methods''). Neuroprotection, represented as the presence of more living cells than control (100 %), is present after 24 h exposure to 1 nM thrombin (n = 8; p value = 0.0004). Moderate concentrations of thrombin (5 and 10 nM) are neutral with regard to cell viability and exposure to high dose thrombin (100 nM) is neurotoxic (n = 8; p value = 0.0046). For comparison, the excitotoxic effects of 24 h exposure to 250 lM glutamate are also shown (n = 8; p value = 0.0135) III demonstrated no significant effects on cortical neuron survival after 24-h exposure at concentrations 50 % or lower than serum concentrations (Fig. 4) . However, a decrease in neuronal viability of nearly 45 % (55.7 ± 26.7 %; p value = 0.0452) was apparent when cultured neurons were exposed to normal serum concentrations (100 %). This is in contrast to argatroban and aprotinin which showed an increase in cell viability. Although it is possible that serum levels of AT III exert neurotoxic effects on cultured neurons, it seems more plausible that this is evidence to support the notion that our cultured cortical neurons are producing and secreting a low-concentration of thrombin in vitro. Additionally, it is possible that the concentrations of argatroban and aprotinin applied resulted in a thrombin concentration within the optimum range. Although we did not directly measure thrombin levels in our culture media due to the difficulty in quantifying this labile enzyme, it has previously been shown by others that neurons express thrombin in vitro [25] .
Thrombin Receptor Activation Mediates Neuroprotection and Fails to Produce Neurotoxicity at High Concentrations
The PAR1 agonist, TRAP (SFLLRN), was used to attempt to identify the role of the thrombin receptor in mediating thrombin's effects on neurons. We attempted to saturate the thrombin receptor with micromolar concentrations of TRAP, and found that neurons incubated for 24 h with TRAP did not exhibit any detrimental effects on neuron survival (Fig. 5) . In fact, activation of the thrombin receptor by 10 lM TRAP appeared to be neuroprotective (116 ± 7.9 %; p value = 0.0251). Higher concentrations of TRAP had no significant effects on cell viability (100 lM, 96.7 ± 12.2 %; 200 lM, 90.1 ± 20.9 %; Fig. 5 ). This is in contrast to the results seen in this assay by applying thrombin in nanomolar concentrations (see Fig. 2) ; thereby, highlighting a distinction between thrombin's receptor-dependent and receptor independent effects.
Thrombin Receptor Activating Peptide (TRAP) Does not Inhibit Neurite Extension
We examined the effects of these same concentrations of TRAP using the more sensitive indicator of neuronal health, morphometric analysis of dendritic extensions (Fig. 6) . In contrast to the effects of thrombin on dendritic growth, TRAP had a neutral effect. The total neurite lengths per neuron (in microns) for the tested TRAP concentrations were (mean ± SD): control, 896 ± 261; 10 lM, 719.2 ± 371; 100 lM, 908. ). None of the tested concentrations of aprotinin or argatroban resulted in neurotoxicity. The largest neuroprotective effect was seen with the addition of 100 kIU/mL aprotinin (p value = 0.0009, n = 4 for each condition). Exposure to all tested doses of argatroban resulted in a significant enhancement of neuronal viability (0.04 lM p value = 0.0341, 0.4 lM p value \0.0001, 4 lM p value = 0.0128; each n = 8). b In the presence of a known neuronal insult, 24-h exposure to 250 lM glutamate, low-dose thrombin enhances neuronal viability (p value \0.0001). c In the presence of a known neuronal insult, 24-h exposure to 250 lM glutamate, co-application of aprotinin doesn't significantly enhance neuronal viability, but does appear to somewhat mitigate the detrimental effects of glutamate. The excitotoxic effects of 24 h exposure to 250 lM glutamate are also shown as a comparison to control conditions (p value = 0.0138). The bars depicting rescue of cell viability by aprotinin are indistinguishable from control conditions. Only at the aprotinin 100 kIU/mL concentration did the difference reach significance when compared to exposure to glutamate alone (not marked on graph, p = 0.0468) number of branches per neuron for the tested TRAP concentrations were (mean ± SD): control, 10.7 ± 2.88; 10 lM, 10.5 ± 2.67; 100 lM, 11.2 ± 4.66; 200 lM,
Discussion
This study demonstrates that (1) thrombin shows an inverted U effect on viability and morphology of rat cortical neuron enriched cultures, and (2) thrombin's neurotoxic effects are complex, but do not appear to depend on signaling through PAR receptors. Using two different assays, we found that exposing cultured neurons to low concentrations of thrombin (1 nM) enhances neurite growth and branching, neuron viability, and protects against excitotoxic damage from glutamate exposure. In contrast, higher concentrations of thrombin (100 nM) are detrimental to neuronal health as evidenced by viability assays and inhibition of neurite growth. These concentrations are within the physiologic range of circulating thrombin which is estimated to vary from \1 nM to over 500 nM during hemostasis [15] . Previous studies have mainly focused on the detrimental effects of thrombin on neurons and the brain [26] [27] [28] [29] and the beneficial effects of suppression of thrombin activity [23, 30, 31] . However, thrombin's role in regulating both neuronal development and the nervous system's response to injury has also been highlighted [13, 32, 33] . Additionally, thrombin has shown some potential therapeutic value via preconditioning [34] . Our demonstration of a non-toxic neuroprotection mediated by low-concentration thrombin (1 nM) aligns well with studies on the peripheral nervous system, which showed important effects of lowconcentration thrombin in neuromuscular junction development [35] and in promoting motoneuron regeneration after injury [32] . An inverted U effect of thrombin concentration on brain cells experiencing hypoglycemic stress has been reported in the past [3] ; however our study is the first demonstration of neuroprotective effects of thrombin on viability and microarchitecture in primary cortical neurons (glial-reduced cultures) in response to excitotoxic damage.
Results from co-application of thrombin and glutamate were both expected and surprising. Low concentrations of thrombin blocked excitotoxic effects of glutamate. This may be consistent with previous observations that activated protein C (APC) blocks glutamate-induced neurotoxicity in cultured hippocampal and cortical neurons [36] since binding of thrombin is necessary to convert the inactive zymogen (protein C) to the activated form. Thus, low concentration thrombin might be expected to provide protection from glutamate. It is less clear why a high concentration of thrombin (100 nM) also blocked the excitotoxic effects of glutamate in our cells. It may be that neuronal mechanisms of thrombin toxicity are altered in the presence of glutamate such that protective effects of APC predominate.
Our experiments with the known inhibitors of thrombin (argatroban and AT III) and other serine proteases (aprotinin) provide a context to evaluate thrombin's dual role in neuroprotection. First, micromolar application of the thrombin receptor agonist peptide, TRAP, in contrast to thrombin toward the high range of serum concentration (100 nM), did not adversely affect neuronal viability. TRAP did not reduce neurite outgrowth or branching and at low concentrations even enhanced neuronal viability in our MTT assay. Because PAR-1 activation did not completely reproduce the effects of exogenously applied thrombin on neuronal health, we suggest a need to delineate between thrombin's cellular effects (mediated through activation of PAR-1) and thrombin's general enzymatic effects (which may involve proteolytic activity at sites other than its receptor). Second, we provide evidence that the efficacy of low concentrations of thrombin in preserving neuronal health is comparable to the serpin aprotinin and to the direct thrombin inhibitor, argatroban. These effects mirror those by exogenous activation of the thrombin receptor via TRAP. As a direct thrombin inhibitor, argatroban blocks the active site of thrombin, and previous reports of neuroprotection by argatroban have focused on reversing thrombin's detrimental effects [30] . Our observations contribute to this body of work by demonstrating no adverse neuronal consequences by PAR-1 receptor activation (at concentrations as high as 200 lM) in brain cell cultures enriched for cortical neurons. This is consistent with thrombin's protective effects being mediated through PAR-1 and its neurotoxic effects due possibly to off-target proteolysis by thrombin in high concentration. However, activation of the PAR-1 receptor by our highest concentrations of TRAP does not result in increased neuroprotection. The endogenous substance AT III, in contrast to argatroban, did not confer neuroprotection. As concentration of exogenous AT III increases, viability may be affected in our in vitro model through thrombin independent effects. Our experiments cannot directly answer the mechanism of neurotoxicity via application of thrombin at high concentrations. Perhaps some of thrombin's neurotoxic effects in high concentrations are mediated by less specific proteolytic cleavage of other membrane proteins besides the PAR-1 receptor. Future experiments using these proteolytic inhibitors in combination with accurate measures of thrombin concentration in PAR-1 knockout animals could aid in the investigation of mechanisms of thrombin's neurotoxic effects independent of the receptor. Another mechanism to explore is calcium regulation in the cellular microenvironment, because both activation of PAR-1 [37] and glutamate [38] are known to increase intracellular calcium.
Despite preclinical evidence of potent neuroprotection, drugs that affect coagulation have yet to be clinically investigated for neuroprotection during ischemic stroke or other neurologic disorders. Our results must also be considered in light of the limitations of in vitro assays. We recognize that thrombin concentration is dynamic in the brain especially in the setting of injury, however we attempted to mimic physiological conditions by adding concentrations of exogenous thrombin in the measured physiologic range [15] . At present, technical limitations prevent accurate measurement of rat thrombin produced in these cortical neuron cultures. However, we are fortunate to be able to apply species specific antithrombin III to our cultures. Based on other published results [39] we consider healthy neurite extension and branching as a sign of good neuronal health in our in vitro system focused on matured neurons. However developmental effects are difficult to isolate in this system and our work should not be considered with regard to thrombin's effects on neuronal development. Care should be taken to not confuse our results in the context of neuroprotection by neuroserpin. While neuroserpin is a serine protease inhibitor actively investigated for neuroprotective potential, it does not appear to affect thrombin activity but instead binds and inactivates plasminogen activators like tPA/uPA [40] . Similarly, although the MTT assay has been used by our lab and several others to assess neuronal viability in vitro, it gives no information about whether the cell death is due to necrosis or apoptosis. Future experiments that track specific markers of apoptosis or necrosis would be necessary to distinguish between these two possibilities.
With appropriate regulation, thrombin plays a normal and protective role in the brain. In situations of blood brain barrier compromise such as trauma, hemorrhagic stroke, cerebral ischemia, or status epilepticus, excess amounts of thrombin from local sources or from the systemic circulation can result in a worsening of pathologic effects on the neurons and glial cells. Thrombin stimulates astrocyte proliferation, angiogenesis, and attracts inflammatory cells. This leads to the inflammation and glial scar formation often seen in head injury. Less specific enzymatic activity of excess thrombin that does not involve its receptor could have direct negative consequences on neuronal function as suggested by our viability assays and morphometric results. Activation of thrombin receptors combined with specific inhibition of thrombin's enzymatic activity (via direct inhibitors such as argatroban) could capitalize on the developmental regulatory functions and neuroprotective effects of thrombin receptor activation while minimizing pro-inflammatory and neurotoxic features of thrombin. Future translational studies could focus on the therapeutic combination of specific manipulation of thrombin concentration with direct receptor activation.
